{"entity":{"id":"nct05903092","kind":"trial","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","aka":["MOZART"],"tldr":"A phase 2 trial of durvalumab, monalizumab and etoposide in lung cancer, run by Hirva Mamdani, now recruiting.","summary":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer is a phase 2, interventional study registered as NCT05903092 by Hirva Mamdani, with a registry enrolment figure of 84 participants, started 2023-09-26 and due to reach its primary completion in 2029-10-31. Interventions recorded: Durvalumab; Monalizumab; Carboplatin or Cisplatin; Etoposide. Conditions listed: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer; Limited Stage Small-Cell Lung Cancer. Primary outcome: 1 year Progression Free Survival (PFS); Safety and Tolerability. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed diagnosis of small cell lung cancer:\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05903092","url":"https://clinicaltrials.gov/study/NCT05903092"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["durvalumab","monalizumab","etoposide"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05903092","phase":"2","setting":"A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)","sponsor":"Hirva Mamdani","enrolled":84,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05903092/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}